Business · 10/06/2021Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for SARCLISA Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for SARCLISA, a human biological product patent extension, following a submission to the US Patent and Trademark Office (USPTO)
Original source language: Federal Register — Food and Drug AdministrationOpen original release →